MAPT and Brain atrophy: Positron emission tomography (PET), fluid biomarker, and neuropathological studies1,2,3,4,5 have consistently demonstrated an association between increased pathological tau and decreased cognitive function and brain atrophy across the Alzheimer disease (AD) spectrum.